Fennec Pharmaceuticals Inc. (FENC) Stock Ticker
FENC right now
Market factors today
Unlock the full FENC picture
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
FENC stock facts
| Ticker symbol | FENC |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $368.4M |
| CEO | Jeffrey S. Hackman |
| Employees | 35 |
| Headquarters | Research Triangle Park, NC, US |
| IPO date | 2017-09-15 |
| Website | www.fennecpharma.com |
What you can see for FENC on Tickr
Live FENC price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the FENC report.
Rankings
FAQ
What is the ticker symbol for Fennec Pharmaceuticals Inc.?
The ticker symbol for Fennec Pharmaceuticals Inc. is FENC, listed on the NASDAQ Capital Market.
What is FENC?
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the…